Due to the COVID-19 pandemic, the ACP office is now closed as our staff work remotely. Click here to see how this impacts our programs and operations.

TYPE II DRUG RECALL: Chlorhexidine Gluconate Solution BP (20%), Lots: 56407/A, 56407/B and 56407/C

August 27, 2014

The supplier of Medisca’s Chlorhexidine Gluconate Solution BP (20%), Lots: 56407/A, 56407/B and 56407/C has issued a recall due to the product being contaminated with the bacteria Serratia Marcescens.

To date, Medisca has not received any adverse event reaction notifications from customers; however, as a precaution Medisca has determined that the situation warrants a recall. Medisca has classified this recall as a Type II, defined in Health Canada policy POL-0160 as “a situation in which the use of, or exposure to, a product may cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote.”

See the recall notice for details and product return procedures. 


← Previous ArticleNext Article →